Implantable Cardiac Kirigami-Inspired Lead-Based Energy Harvester Fabricated by Enhanced Piezoelectric Composite Film.

Harvesting biomechanical energy to power implantable electronics such as pacemakers has been attracting great attention in recent years because it replaces conventional batteries and provides a sustainable energy solution. However, current energy harvesting technologies that directly interact with internal organs often lack flexibility and conformability, and they usually require additional implantation surgeries that impose extra burden to patients. To address this issue, here a Kirigami inspired energy harvester, seamlessly incorporated into the pacemaker lead using piezoelectric composite films is reported, which not only possesses great flexibility but also requires no additional implantation surgeries.

Flexible Energy Harvester on a Pacemaker Lead Using Multibeam Piezoelectric Composite Thin Films.

Implantable medical devices, such as cardiac pacemakers and defibrillators, rely on batteries for operation. However, conventional batteries only last for a few years, and additional surgeries are needed for replacement. Harvesting energy directly from the human body enables a new paradigm of self-sustainable power sources for implantable medical devices without being constrained by the battery's limited lifetime.

Multifunctional Pacemaker Lead for Cardiac Energy Harvesting and Pressure Sensing.

Biomedical self-sustainable energy generation represents a new frontier of power solution for implantable biomedical devices (IMDs), such as cardiac pacemakers. However, almost all reported cardiac energy harvesting designs have not yet reached the stage of clinical translation. A major bottleneck has been the need of additional surgeries for the placements of these devices.

Trabecular cutting: a novel surgical therapy to increase diastolic compliance.

Heart failure with preserved ejection fraction (HFpEF) is a common cause of hospital admission in patients over 65 yr old and has high mortality. HFpEF is characterized by left ventricular (LV) hypertrophy that reduces compliance. Current HFpEF therapies control symptoms, but no existing medications or therapies can sustainably increase LV compliance.